Biologics · Aug 10, 2021

Utah Cord Bank LLC dba Utah Cell Bank

9 extracted findings

FDA source excerpt, selected passage

Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].** For example:

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Findings extracted from the letter

Selected FDA passages, not the complete letter.

Failure to have separate or defined areas or such other control systems for your operations as are necessary to prevent contamination or mixups during the course of aseptic processing. [21 CFR 211.42(c)(10)].** For example:

Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].** For example:

Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].** Specifically, the manufacturing processes for your products have not been validated.

Failure to establish and follow written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures [21 CFR 211.80(a)].** For example:

Failure to establish and follow written procedures for cleaning and maintenance of equipment used in the manufacture, processing, packing, or holding of a drug product [21 CFR 211.67(b)].** For example:

Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine the appropriate storage conditions and expiration dates [21 CFR 211.166(a)].** Specifically, you assign a two-to-six year expiration date to your products without supporting data.

Failure to establish and follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)].** For example:

Failure to prepare batch production and control records for each batch of drug product produced that include complete information relating to the production and control of each batch, including documentation that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished [21 CFR 211.188(b)].** For example:

Sections and clauses cited

As cited in this historical letter, not a statement of current regulatory requirements.

Utah Cord Bank LLC dba Utah Cell Bank

Findings and supporting evidence

Findings extracted from the letter

Sections and clauses cited

More biologics letters

Keep exploring

Put this kind of reading to
work on your own records.

FDA Warning Letter Alerts

Findings and supporting evidence

Findings extracted from the letter

Sections and clauses cited

More biologics letters

Keep exploring

Put this kind of reading towork on your own records.

Put this kind of reading to
work on your own records.